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Exercise and Hormones
increase in RBF and may be an important regulatory mechanism of renal
circulation in pts with CHF.
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Human skeletal alpha actin expression was present in all samples.
Conclusions: The frequency of iNOS expression was increased (p < 0.02)
in right ventricular tissue from patients with head failure irrespective of etiol-
ogy. Although this phenomenon might result from the effects of drug therapy
andlor cardiac surgical procedures, it may be that expression of iNOS, like
AN P, is part of the molecular phenotype of the failing heart Local generation
of increased levels of nitric oxide may contribute to contractile impairment in
patients with valvular and ischemic head disease as well as in patients with
dilated cardiomyopathy.
Nitric oxide is known to exert negative inotropic effects on myocytes. Ini-
tial reports using activity assays have suggested increased generation of
nitric oxide in myocardium from patients with dilated cardiomyopathy and
acute myocarditis. However, myocardial detection of mRNA encoding the
cytokine-inducible form of nitric oxide synthase(iNOS) has not been reported
in patients with heart failure. We extracted total RNA from right ventricular
myocardium obtained from 40 human hearts; explanted hearts -dilated car-
diomyopathy (n ~ 10), ischemic head disease (n ~ 10); intra-operative biop-
sies in patients with compensated heart failure - valvular heart disease (n =
9) ischemic heart disease (n ~ 1); and necropsy specimens (within 6 hours
of death) from subjects who had suffered sudden death from a non-cardiac
cause (n ~ 10). Samples were analyzed using reverse transcription - poly-
merase chain reaction (RT-PCR). Three pairs of oligonucleotide primers were
used that were specific for iNOS, atrial natriuretic peptide (ANP) and human
skeletal alpha actin. Expression of ANP in human ventricular myocardium
has been shown to be a marker of changes in gene expression associated
with heart failure and ventricular remodeling, and human skeletal alpha actin
was used as an internal standard to indicate the presence of non-degraded
mRNA.
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I 779-6! Human Inducible Nitric Oxide Synthase is Expressed
in Dilated Cardiomyopathy, Valvular and Ischemic
Heart Disease
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1780-1 I Exercise-induced ST Segment Depression is
Associated with Increases in Endothelin-1
Wendy S. Shear, Cheryl L. lacarella, Rosemary V. Manion, Betsy V. Christensen,
Dianne L. Judd, Robert F. Wilson University of Minnesota, Minneapolis, Minnesota
We have shown previously that plasma [N021(a metabolite of nitric oxide)
rises sharply during exercise in normal subjects, but does not increase sig-
nificantly in patients with exercise-induced ST depression and angiograph-
ically normal coronary arteries. To determine if venous plasma endothelin-
1, a potent endothelial-dependent vasoconstrictor, changes with exercise,
we studied 17 subjects (7 with normal exercise ECGs and 10 with exercise-
induced ST depression ~0.1 mV after the J point) using symptom-limited
exercise treadmill tests. Plasma endothelin-l levels were measured using a
radioimmunoassay at baseline (Basal). peak exercise (Peak). and 5 minutes
post-exercise (post).
Results:
Plasma Endothelin-l (pg/ml)
Pre-CHF Day 10-CHF Day 2!>-CHF Day 30-CHF
EF 53 ± 2 30 ± 4* 24 ± 2*t 21 ± l*t
MAP 106± 2 110 ± 5 101 ± 4 94 ± 6*t
NO 6.8 ± 0.04 96 ± 1.1 10.6± lA* 6.2 ± 0.2"
ANP 37 ± 5 257 ± 85* 574 ± 35*t 572 ± 83*t
cGMP 4.1 ± 0.3 12.5±09* 20.1 ± 2.5*t 193 ± 2.4*t
PRA 0.98 ± OA 1.7 ± 0.7 1.7 ± 08 7.2 ± 2.2*t"
UNaV 44 ± 4 42 ± 2 24 ± 6 16 ± 9*t
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Tracy L. Stevens, Daniel D. Borgeson, Lawrence L. Aahrus, Margaret M. Redfield,
Debra A. Lewis, Paul W. Wennberg, John C. Burnett, Jr. Mayo Clinic and Foundation,
Rochester. MN
Congestive heart failure (CHF), a syndrome which progresses from a com-
pensated to a decompensated state, is characterized by maintenance of
sodium excretion without activation of the renin-angiotensin system (RAS)
to a state of sodium retention with an activated RAS. While a role for atrial
natriuretic peptide (ANP) in maintaining this initial state of compensation
has been advanced, controversy persists with regard to the activity of the
endogenous nitric oxide (NO) system in CHF. Such controversy may reflect
temporal changes in the endogenous NO system not previously observed.
Like ANp, NO also possesses important vasodilatory, natriuretic and renin-
inhibiting actions via activation of cGMP. The objective of the current study
was to determine the temporal changes in plasma nitric oxide as deter-
mined by chemiluminescence and associated changes in plasma ANp, cGMP,
plasma renin activity and sodium excretion. We defined these parameters in
a unique canine model of progressive CHF produced by incremental rapid
ventricular pacing (180 bpm to 240 bpm, n ~ 51 over a 30 day period.
*p < 0.05 Vs Pre-CHF; t p < 0.05 vs Day 1O-CHF; "p < 0.05 vs Day 25-CHF
EF, ejection fraction (%); MAP, mean arterial pressure (mmHg); NO, nitrate
InmollmL); ANp, (pg/mL); cGMP, plasma cGMP(pmollmL); PRA, plasma renin
activity (ng/mL/hrl: UNaV, urinary sodium excretion (mEql24 hr).
These studies demonstrate a unique biphasic response in plasma NO as
characterized by an increase in NO during the initial compensated phase of
CHF, followed by a decrease with the onset of avid sodium retention and
activation of the RAS. These studies provide evidence for NO as a partici-
pant in the adaptive changes in the cardiorenal and humoral systems with
progressive heart failure.
1779-41 Biphasic Alterations in Plasma Nitric Oxide in
Experimental Progressive Heart Failure
RAP RVP CSA RBF RVR
mmH9 mmHg mm 2 ml/min dynes.cm-5
BLl 91 ±4 10 ± 1.0 3.7 ± 03 610 ± 46 11171 ± 1295
ACh 10-8M 88 ± 4 10 ± Og 3.8 ± OA' 1015 ± 118' 6685 ± 723'
1O-7M 87 ± 4 10 ± 0.8 3.9 ± 03' l360± 154' 5188 ± 805'
1O-6M 90 ± 4 11 ± 0.9 4.0 ± 0.3' 1499 ± 181' 4868 ± 660'
BL2 91 ± 3 10 ± 1.0 3.5 ± 0.3 635 ± 30 10275 ± 931
NTG 1O-7M 91 ± 4 10 ± 10 37 ± O.3t 782 ± 80 8842 ± 1060
10-6M 95 ± 4 10 ± 1.0 39 ± 0.3t 753 ± 78 9972 ± 1415
1O-5M 89 ± 3 10± 11 3.9 ± 03t 755 ± 58 8595 ± 809
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1779-51 The Effect of Endothelial Stimulation on the Renal
Circulation in Patients with Chronic Heart Failure
Gregory Cohen, Harinder Gogia, Anilkumar Mehra, P. Anthony N. Chandraratna,
Janet V. Johnson, Uri Elkayam. USC School ofMedicine, Los Angeles, CA
Impairment of renal blood flow (RBF) is common in pts with chronic heart
failure (CHF) and may lead to renal dysfunction. Although abnormal RBF
may be due to depressed cardiac output, individual correlations are weak
and suggest for local vasoregulatory mechanisms. We assessed the role
of endothelium (END) derived nitric oxide (NO) on the renal circulation in
12 pts with CHF. Acetylcholine (ACh) (END-dependent vasodilator) and nitro-
glycerin (NTG) (END-independent vasodilator) were infused in a randomized,
crossover design into the renal artery (RA). Effects on renal arterial (RAP) and
renal venous IRVP) pressures, RA cross sectional area (CSA), RBF and renal
vascular resistance (RVR) were studied. CSA was measured by intravascular
ultrasound and RA flow velocity by a Doppler flow wire. The results were as
follows;
mean ± SEM, *p < 005 vs Normal
Exercise time and peak HR x SBP were similar between the two
groups (13,7 ± 0.8 vs 13.3 ± 0.5 min and 30.0 ± 2.7 vs 29.9 ± 1.4
'p < 0.05 vs Baseline 1 IBL1); t p < 005 vs Baseline 2 (BL2)
Conclusion: 1) Exogenous NO (NTG) causes a vasodilatory effect on re-
nal conductance but not on resistance vessels; 2) In contrast, stimulation
of endothelium-derived NO results in a significant vasodilation of both con-
ductance and resistance vessels. This effect leads to reduction in RVR and
Normal
ST i
29 ± 0.7
3.9 ± 09
1.6 ± 0.5
7.5± 21*
2.2 ± 0.6
5.2 ± 1A
-14 ± 0.7
+3.6 ± 1.8*
